Abstract
Blastocystis sp. is a commonly found intestinal microorganism and was reported to cause many nonspecific gastrointestinal symptoms. Various subtypes have been previously reported, and the pathogenicity of different subtypes of Blastocystis is unclear and remains as a controversial issue. A recent study has shown that the Blastocystis antigen isolated from an unknown subtype could facilitate the proliferation of colon cancer cells. Current study was conducted to compare the effect of solubilized antigen isolated from five different subtypes of Blastocystis on colon cancer cells, HCT116. A statistically significant proliferation of these cells was observed when exposed to 1.0 μg/ml solubilized antigen isolated from subtype 3 Blastocystis (37.22 %, p < 0.05). Real-time polymerase chain reaction demonstrated the upregulation of Th2 cytokines especially transforming growth factor beta in subtype 3-treated cancer cells (p < 0.01, 3.71-fold difference). Of interest, subtype 3 Blastocystis antigen also caused a significantly higher upregulation of cathepsin B (subtypes 1 and 2, p < 0.01; subtypes 4 and 5, p < 0.001; 6.71-fold difference) which lead to the postulation that it may enhance the exacerbation of existing colon cancer cells by weakening the cellular immune response. The dysregulation of IFN-γ and p53 expression also suggest Blastocystis as a proponent of carcinogenesis. Therefore, it is very likely for subtype 3 Blastocystis to have higher pathogenic potential as it caused an increased propagation of cancer cells and substantial amount of inflammatory reaction compared to other subtypes.
Similar content being viewed by others
References
Adrover E, Maestro M, Sanz-Casla M, Del Barco V, Cerdán J, Fernández C, Balibrea J (1999) Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Brit J Cancer 81:122
Becker C, Fantini M, Wirtz S, Nikolaev A, Lehr H, Galle P, Rose-John S, Neurath M (2005) Extra views IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:217–220
Chan KH, Chandramathi S, Suresh K, Chua KH, Kuppusamy UR (2012) Effects of symptomatic and asymptomatic isolates of Blastocystis hominis on colorectal cancer cell line, HCT116. Parasitol Res 110:2475–2480
Chandramathi S, Suresh K, Anita Z, Kuppusamy U (2009) Elevated levels of urinary hydrogen peroxide, advanced oxidative protein product (AOPP) and malondialdehyde in humans infected with intestinal parasites. Parasitology 136:359–363
Chandramathi S, Suresh K, Kuppusamy UR (2010) Solubilized antigen of Blastocystis hominis facilitates the growth of human colorectal cancer cells, HCT116. Parasitol Res 106:941–945
Chung YC, Chang YF (2003) Serum interleukin 6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226
Cirioni O, Giacometti A, Drenaggi D, Ancarani F, Scalise G (1999) Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. Eur J Epidemiol 15:387–391
Doyle P, Helgason M, Mathias R, Proctor E (1990) Epidemiology and pathogenicity of Blastocystis hominis. J Clin Microbiol 28:116
Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093
Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178
Herszenyi L, Istvan G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F (2008) Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 17:438–445
Kaneda Y, Horiki N, Cheng X, Fujita Y, Maruyama M, Tachibana H (2001) Ribodemes of Blastocystis hominis isolated in Japan. Amer J Trop Med Hyg 65:393
Long H, Handschack A, König W, Ambrosch A (2001) Blastocystis hominis modulates immune responses and cytokine release in colonic epithelial cells. Parasitol Res 87:1029–1030
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method 65:55–63
Suresh K, Venilla GD, Tan TC, Rohela M (2009) In vivo encystation of Blastocystis hominis. Parasitol Res 104:1373–1380
Tan T, Suresh K, Smith H (2008) Phenotypic and genotypic characterisation of Blastocystis hominis isolates implicates subtype 3 as a subtype with pathogenic potential. Parasitol Res 104:85–93
Windsor J, Macfarlane L, Hughes-Thapa G, Jones S, Whiteside T (2002) Incidence of Blastocystis hominis in faecal samples submitted for routine microbiological analysis. Brit J Biomed Sci 59:154–157
Wong KH, Ng GC, Lin RT, Yoshikawa H, Taylor MB, Tan KS (2008) Predominance of subtype 3 among Blastocystis isolates from a major hospital in Singapore. Parasitol Res 102:663–670
Yoshikawa H, Abe N, Iwasawa M, Kitano S, Nagano I, Wu Z, Takahashi Y (2000) Genomic analysis of Blastocystis hominis strains isolated from two long-term health care facilities. J Clin Microbiol 38:1324
Yoshikawa H, Abe N, Wu Z (2004) PCR-based identification of zoonotic isolates of Blastocystis from mammals and birds. Microbiology-Engl Tr 150:1147
Yoshikawa H, Nagano I, Wu Z, Yap EH, Singh M, Takahashi Y (1998) Genomic polymorphism among Blastocystis hominis strains and development of subtype-specific diagnostic primers. Mol Cell Probe 12:153–159
Acknowledgments
This study was funded by University of Malaya High Impact Grant (UM.C/625/1/HIR).
Author information
Authors and Affiliations
Corresponding author
Additional information
Vinoth Kumarasamy, Umah R. Kuppusamy, and Chandramathi Samudi contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kumarasamy, V., Kuppusamy, U.R., Samudi, C. et al. Blastocystis sp. subtype 3 triggers higher proliferation of human colorectal cancer cells, HCT116. Parasitol Res 112, 3551–3555 (2013). https://doi.org/10.1007/s00436-013-3538-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-013-3538-5